Literature DB >> 17599445

Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT).

John D Fisher1, Alfred E Buxton, Kerry L Lee, Douglas L Packer, Debra S Echt, Pablo Denes, Michael H Lehmann, John P DiMarco, Denis Roy, Gail E Hafley.   

Abstract

Patients with coronary artery disease, depressed left ventricular ejection fraction, and nonsustained ventricular tachycardia (VT) have a high mortality rate due to arrhythmic (arrhythmic death/cardiac arrest) and other cardiac causes. The Multicenter UnSustained Tachycardia Trial (MUSTT) investigated whether electrophysiologic study (EPS) was helpful in choosing drug or defibrillator therapy in patients induced into sustained VT. The events committee attempted to categorize follow-up events in patients in MUSTT and to present a detailed breakdown of events. A derivative of the Hinkle-Thaler classification was used, incorporating lessons from other multicenter studies. The committee was blinded to results of EPS and implantable cardioverter-defibrillator (ICD) or other antiarrhythmic therapy status of patients. The primary end point was cardiac arrest or death from arrhythmia. Secondary end points were death from all causes, cardiac causes, and spontaneous sustained VT. Classifications were death and cardiac arrest. Each was similarly divided as arrhythmic with 14 subcategories, e.g., unwitnessed or related to EPS and nonarrhythmic with 10 subcategories, e.g., ischemia. Terminal VF in progressive heart failure was considered nonarrhythmic. Events were reviewed by 2 members. Disagreements were resolved by the 2 members or, if needed, by the full committee. Of the 2,202 patients in MUSTT, there were 902 deaths. Sustained VT requiring cardioversion occurred in 182 patients. An additional 94 patients had resuscitated cardiac arrests. Events occurred in 1,027 patients, and all were reviewed. The 3 leading events were deaths that were classed as sudden/unwitnessed (23% of 902), due to progressive heart failure (22%), or due to noncardiovascular causes (18%). Arrhythmic deaths or cardiac arrests were highest in inducible patients randomized to no antiarrhythmic therapy; next were inducible patients receiving an ICD; and lowest were in patients who were noninducible. In conclusion, the classification system provided a detailed breakdown of events in consistent categories, showing utility for event analysis and interpretation and development of therapeutic strategies. The classifications assigned by the committee were used in all MUSTT outcomes reports, thus affecting all reported outcomes and overall interpretations of the MUSTT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599445      PMCID: PMC4733349          DOI: 10.1016/j.amjcard.2007.02.055

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

Review 1.  Recommended guidelines for uniform reporting of data from out-of-hospital cardiac arrest: the Utstein Style. A statement for health professionals from a task force of the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, and the Australian Resuscitation Council.

Authors:  R O Cummins; D A Chamberlain; N S Abramson; M Allen; P J Baskett; L Becker; L Bossaert; H H Delooz; W F Dick; M S Eisenberg
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

2.  Standardized reporting of ICD patient outcome: the report of a North American Society of Pacing and Electrophysiology Policy Conference, February 9-10, 1993.

Authors:  S G Kim; R N Fogoros; S Furman; S J Connolly; K H Kuck; A J Moss
Journal:  Pacing Clin Electrophysiol       Date:  1993-07       Impact factor: 1.976

3.  Prediction of long-term outcomes by signal-averaged electrocardiography in patients with unsustained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction.

Authors:  J A Gomes; M E Cain; A E Buxton; M E Josephson; K L Lee; G E Hafley
Journal:  Circulation       Date:  2001-07-24       Impact factor: 29.690

4.  Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery.

Authors:  J T Bigger; W Whang; J N Rottman; R E Kleiger; C D Gottlieb; P B Namerow; R C Steinman; N A Estes
Journal:  Circulation       Date:  1999-03-23       Impact factor: 29.690

5.  Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.

Authors: 
Journal:  J Am Coll Cardiol       Date:  1999-11-01       Impact factor: 24.094

6.  Nonsustained ventricular tachycardia in coronary artery disease: relation to inducible sustained ventricular tachycardia. MUSTT Investigators.

Authors:  A E Buxton; K L Lee; L DiCarlo; D S Echt; J D Fisher; G S Greer; M E Josephson; D Packer; E N Prystowsky; M Talajíc
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

7.  Classification of death in patients under antiarrhythmic treatment.

Authors:  H Ector; R Rogers; A Rubens; H De Geest
Journal:  Pacing Clin Electrophysiol       Date:  1993-12       Impact factor: 1.976

8.  Effect of implantable defibrillators on arrhythmic events and mortality in the multicenter unsustained tachycardia trial.

Authors:  Kerry L Lee; Gail Hafley; John D Fisher; Michael R Gold; Eric N Prystowsky; Mario Talajic; Mark E Josephson; Douglas L Packer; Alfred E Buxton
Journal:  Circulation       Date:  2002-07-09       Impact factor: 29.690

9.  Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials.

Authors:  C M Pratt; P S Greenway; M H Schoenfeld; M L Hibben; J A Reiffel
Journal:  Circulation       Date:  1996-02-01       Impact factor: 29.690

10.  Prognostic significance of nonsustained ventricular tachycardia identified postoperatively after coronary artery bypass surgery in patients with left ventricular dysfunction.

Authors:  Luis A Pires; Gail E Hafley; Kerry L Lee; John D Fisher; Mark E Josephson; Eric N Prystowsky; Alfred E Buxton
Journal:  J Cardiovasc Electrophysiol       Date:  2002-08
View more
  6 in total

1.  Predicting cardiac events using ventricular dyssynchrony in patients who received implantable cardioverter defibrillators: Are more treatment options required?

Authors:  Keiichiro Yoshinaga
Journal:  J Nucl Cardiol       Date:  2015-11-24       Impact factor: 5.952

Review 2.  The genetics of sudden cardiac death.

Authors:  Dan E Arking; Nona Sotoodehnia
Journal:  Annu Rev Genomics Hum Genet       Date:  2012-06-11       Impact factor: 8.929

3.  Relation of left-ventricular dyssynchrony by phase analysis of gated SPECT images and cardiovascular events in patients with implantable cardiac defibrillators.

Authors:  Wael A Aljaroudi; Fadi G Hage; Daniel Hermann; Harish Doppalapudi; Rajesh Venkataraman; Jaekyeong Heo; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2010-03-19       Impact factor: 5.952

Review 4.  A systematic review of the association between obstructive sleep apnea and ventricular arrhythmias.

Authors:  Akhil Raghuram; Ryan Clay; Anusha Kumbam; Larisa G Tereshchenko; Akram Khan
Journal:  J Clin Sleep Med       Date:  2014-10-15       Impact factor: 4.062

5.  Yield of left ventricular dyssynchrony by gated SPECT MPI in patients with heart failure prior to implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator: Characteristics and prediction of cardiac outcome.

Authors:  Nili Zafrir; Tamir Bental; Boris Strasberg; Alejandro Solodky; Israel Mats; Ariel Gutstein; Ran Kornowski
Journal:  J Nucl Cardiol       Date:  2015-11-12       Impact factor: 5.952

6.  Prognostic value of left ventricular dyssynchrony by myocardial perfusion-gated SPECT in patients with normal and abnormal left ventricular functions.

Authors:  Nili Zafrir; Roman Nevzorov; Tamir Bental; Boris Strasberg; Ariel Gutstein; Israel Mats; Ran Kornowski; Alejandro Solodky
Journal:  J Nucl Cardiol       Date:  2014-03-13       Impact factor: 5.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.